17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093 India

Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

Sun Pharma announces USFDA approval for generic Imitrex® injection First ANDA approval for a Sumatriptan AutoInjector

Mumbai, June 21, 2011: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sumatriptan Succinate Injection, 6 mg (base) / 0.5mL. This is the first ANDA approval for a Sumatriptan AutoInjector.

This generic Sumatriptan Succinate Injection packaged in a Single-Dose Syringe with AutoInjector is equivalent to Imitrex® STATdose System, 6 mg (base) / 0.5 mL of GlaxoSmithKline. Annual sale for Sumatriptan Succinate Injections in the US is approximately \$ 190 million.

Sumatriptan succinate injection is indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes.

Imitrex® is a registered trademark of GlaxoSmithKline.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics, ophthalmology and nephrology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota Mira Desai

Tel +91 22 6645 5645, Xtn 605 Tel +91 22 6645 5645, Xtn 606
Tel Direct +91 22 66455605 Tel Direct +91 22 66455606
Mobile +91 98670 10529 Mobile +91 98219 23797

E mail <u>uday.baldota@sunpharma.com</u> E mail <u>mira.desai@sunpharma.com</u>